Innovation in Translational Oncology Research
On April 21st, Crown Bioscience announced its partnership with Turbine to integrate AI-driven predictive models with organoid validation, aiming to advance translational oncology research. This strategic collaboration seeks to enhance the efficiency of moving from hypothesis to validation.
Turbine’s Virtual Assays simulate biological responses across thousands of samples and hundreds of drugs, providing predictive insights that help prioritise therapeutic targets. Meanwhile, Crown Bioscience applies these predictions using approximately 1,000 tumor organoid models based on HUB Organoid Technology. The integration of these technologies establishes a connected workflow for researchers.
The companies aim to improve predictive accuracy by incorporating multimodal and drug response data from Crown’s tumor organoid models. As a result, this partnership helps reduce the experimental burden and delivers greater biological relevance and translational confidence.
According to John Gu, CEO of Crown Bioscience, “By integrating predictive modelling with our organoid models, we are creating a more robust foundation for decision-making, one that improves confidence, reduces risk, and accelerates the path to the clinic.” The closed-loop system enhances the reliability of predictions in clinical settings.
Enhancing Predictive Accuracy and Reducing Costs
By using Turbine’s Virtual Lab, researchers can explore millions of hypotheses in silico. This virtual experimentation is integrated with Crown’s organoid platform, which better reflects patient biology and aims to address the trade-off between scale and translatability. Szabolcs Nagy, CEO of Turbine, emphasised the importance of this collaboration in advancing drug discovery.
Crown Bioscience, a global contract research organisation, is dedicated to accelerating drug discovery and development in oncology and immuno-oncology. The company provides innovative solutions that span preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft collection and tumor organoid models, Crown offers insights across 35 cancer indications.
This partnership focuses on optimizing resources and improving clinical translatability, enabling researchers to make faster, more informed decisions with greater confidence in clinical outcomes and patient biology.
Last updated: 22 April 2026, 8:19 am
